Gwendolyn Strong Foundation Granting Fifty iPads to those with Spinal Muscular Atrophy (SMA)

January 10, 2012

Gwendolyn Strong Foundation Granting Fifty iPads to those with Spinal Muscular Atrophy (SMA)

Press Release | January 10, 2012

SANTA BARBARA, CA — January 10, 2012 — The Gwendolyn Strong Foundation (theGSF), a Santa Barbara-based nonprofit organization dedicated to increasing global awareness of Spinal Muscular Atrophy (SMA), the #1 genetic killer of young children, and supporting families impacted by SMA and other life-altering conditions, launched its newest initiative called “Project Mariposa”. Project Mariposa has a simple mission: to make the world more accessible to those with severe disabilities through targeted technology product grants.

The program will initially focus on granting iPads to those impacted by SMA. SMA is a degenerative disease that causes weakness and wasting of the voluntary muscles. Cognitive ability is never hindered and those with SMA are bright in spite of their failing bodies. The iPad, coupled with the growing application library that accompanies them, are literally life-changing in assisting with communication, education, and independence. theGSF has secured funding for the initial fifty (50) iPads and will be announcing one (1) grant recipient per week for fifty (50) weeks beginning February 3, 2012.

“The iPad is opening up new avenues that were previously impossible,” said Victoria Strong, theGSF co-founder. “It’s large screen size, light weight, portability, and featherlight touch screen make access to education, entertainment, and independence possible and in some cases it is literally allowing children to communicate for the first time in their lives. Its impact is truly incredible.”

Click HERE or on the image below to read more…


Disabled, seniors worry about cuts to in-home care

January 9, 2012

Disabled, seniors worry about cuts to in-home care

Associated Press | January 7, 2012 | By Judy Lin

Born with spinal muscular atrophy, a genetic disease that prevents muscle development, Anthony Muli has never walked and his doctors never expected him to live past age 2.

Now, at 24, he’s a sports fanatic and a whiz on the computer. His room inside his grandmother’s house in the Northern California town of Loomis, east of Sacramento, is decorated with San Francisco 49ers and Sacramento Kings memorabilia.

He enjoys as much of life as he can with the help of his 72-year-old grandmother and caretaker, Jo Ellen Zerr, who does everything from cleaning his tracheotomy tube to driving him to his medical appointments.

The level of care is made possible in large part because of California’s In-Home Supportive Services program, which helps about 435,000 California seniors and people with disabilities. The program pays caretakers, many of them family members, hourly wages and benefits between $8 and $14.78 to help people get dressed, cook and bathe. For her work, Kerr, a retired clerk, receives about $2,800 a month before taxes to do a job she would do for free.

“I would take care of him regardless,” she said.

Click HERE or on the image below to read more…


Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy

January 4, 2012

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy

Press Release | January 4, 2012

WESTON, Mass. & CARLSBAD, Calif., Jan 04, 2012 (BUSINESS WIRE) — — Biogen Idec’s Expertise in Neurology to Aid in Rapid Development of ISIS-SMNRx —

Biogen Idec BIIB +0.63% and Isis Pharmaceuticals, Inc. ISIS -0.28% today announced that they have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize Isis’ antisense investigational drug, ISIS-SMNRx, for the treatment of spinal muscular atrophy (SMA).

SMA is a genetic neuromuscular disease characterized by muscle atrophy and weakness, and it is the most common genetic cause of infant mortality. One child out of every 10,000 births worldwide is born with SMA. Children with SMA generally appear normal at birth, with symptoms developing as early as a few months after birth, and in the most severe form of the disease, children have a significantly shortened lifespan. Isis’ ISIS-SMNRx is designed to compensate for the underlying genetic defect that causes SMA.

Under the terms of the agreement, Isis will receive an upfront payment of $29 million and is eligible to receive up to $45 million in milestone payments associated with the clinical development of ISIS-SMNRx prior to licensing. Biogen Idec has the option to license ISIS-SMNRx until completion of the first successful Phase 2/3 trial. Isis could receive up to another $225 million in a license fee and regulatory milestone payments. In addition, Isis will receive double-digit royalties on sales of ISIS-SMNRx. Isis will be responsible for global development of ISIS-SMNRx through the completion of Phase 2/3 registrational clinical trials, with Biogen Idec providing advice on the clinical trial design and regulatory strategy. If Biogen Idec exercises its option, it will assume global development, regulatory and commercialization responsibilities.

Click HERE or on the image below to read more…


BioTime to Produce Stem Cells for Research in Muscle Disorders

January 3, 2012

BioTime to Produce Stem Cells for Research in Muscle Disorders

Press Release | January 3, 2012

ALAMEDA, Calif., Jan 03, 2012 (BUSINESS WIRE) — BioTime, Inc. BTX +0.51% today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois. The muscle cell lines will display the genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy. The cell lines will be marketed researchers seeking new treatment modalities for these diseases.

“In the first quarter of this year, we will offer medical researchers normal muscle progenitor cell lines that we have already produced from BioTime’s existing hES cell lines, and later in 2012 we plan to add to our product line the novel muscle progenitor cells produced from RGI cell lines bearing the five genetic muscle diseases,” said Michael West, Ph.D., BioTime’s CEO. “BioTime’s business strategy includes generating near-term revenues in the emerging field of regenerative medicine by bringing some of the most advanced stem cell technologies to the market as research products.”

Click HERE or on the image below to read more…


Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy

December 19, 2011

Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy

Press Release | December 19, 2011

CARLSBAD, Calif., Dec. 19, 2011 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA). SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. Isis is developing ISIS-SMNRx as a potential treatment for all Types of SMA.

“SMA is a devastating disease that leads to the loss of motor neurons resulting in muscle weakness and respiratory failure in children. The genetic cause of this disease is well understood, but there are currently no effective disease-modifying therapies. Currently, treatment of SMA is entirely symptomatic and focuses on preserving muscle strength and lung function by physical therapy and assisted ventilation. This supportive approach has improved the natural history of SMA by extending life expectancy, but muscle weakness and atrophy are not affected. A disease-modifying drug like ISIS-SMNRx that specifically targets the cause of the disease could, for the first time, restore muscle strength and respiratory function and dramatically improve the children’s function and quality of life,” said Darryl C. De Vivo, M.D., Sidney Carter Professor of Neurology and Pediatrics and Co-Director of the Motor Neuron Center at Columbia University Medical Center.

Click HERE or on the image below to read more…


theGSF and FightSMA Award $100,000 Spinal Muscular Atrophy Research Grant

December 16, 2011

theGSF.org | December 15, 2011

The Gwendolyn Strong Foundation (theGSF) and FightSMA are excited to announce a $100,000 award to Dr. Monique A. Lorson and University of Missouri in support of Dr. Lorson’s research focused on developing a large animal model of Spinal Muscular Atrophy (SMA).

Currently, no large animal model of SMA exists and the goal of Dr. Lorson’s research is to develop the first ever pig based model of SMA to be used by the broad, global SMA research community and other research groups to allow them to more efficiently and effectively move promising research from the bench to bedside. In short, this is a very exciting program that has the potential to have a material, positive impact on the future of SMA research in almost every category (e.g. gene therapy, compounds, antisense oligonucleotides).

Click HERE or on the image below to read more…


Runners raise thousands for those who can’t

November 17, 2011

Santa Barbara News-Press | November 13, 2011 | By Nikki Grey

They say they run so that one day those who can’t, can.

Although it takes strength, endurance, and dedication to run a marathon, runners on Team GSF say their sweat leading up to the Santa Barbara International Marathon was nothing compared to what it takes to provide care for a baby that has spinal muscular atrophy.

Representing Santa Barbara-based The Gwendolyn Strong Foundation, 30 runners raised more than $50,000 to spread awareness about the disease, as well as fund research for a cure.

The nonprofit foundation, which was established in 2009 and has raised nearly $1 million for its cause, is not just any organization working to combat a fatal disease.

Created by two Santa Barbara parents who were devastated when they realized a disease they had never even heard of would likely kill their daughter, the organization has spread its message and influence nationwide.

Bill and Victoria Strong say they are humbled by the efforts of the 30 runners to raise money to combat the disease that afflicts 4-year-old Gwendolyn.

“I think this is so powerful that people who can walk or run use their bodies so someday children who can’t, can too,” said Mr. Strong, a 35-year-old Internet entrepreneur.

According to the foundation’s website, spinal muscular atrophy is the No. 1 genetic killer of babies and young children. SMA is a degenerative illness that eventually hinders an individual’s ability to walk, stand, breathe, eat, and swallow.

Mr. Strong said that because of this disease, his daughter is essentially paralyzed and requires around the clock care to stay alive.

The mind, however, is never affected, said Mr. Strong.

“She’s just like any other kid,” he said. “We just try to give Gwendolyn the experiences of any other child. Although the disease is still terminal, her life is now, so we just try to live it that way and give her as many experiences as possible.”

Mrs. Strong, 34, said giving Gwendolyn the life she and her husband want for their daughter can be challenging, but there are always ways to make it work. An example is when Gwendolyn wanted to climb a tree with her preschool classmates. She was lifted into the tree.

Gwendolyn communicates with others, Mrs. Strong said, using her eyes. For “yes,” she rolls her eyes up, and for “no,” she blinks. When Gwendolyn is really excited, she rolls her eyes very fast, Mrs. Strong said.

Members of Team GSF participated in the marathon, half marathon and relay. They raised money mostly by asking friends, families and businesses to sponsor them for the event.

The third annual Santa Barbara International Marathon was Mr. Strong’s first marathon. He said the inspiration of running a marathon to raise awareness and funding for SMA research stemmed from when his friend Michael Paskin raised money for the foundation by participating in the Ironman triathlon in 2009.

Mr. Paskin said he is inspired by the strength the Strong family demonstrates every day.

“What they’re going through is so incredibly difficult and over the course of (Gwendolyn) suffering from SMA, I think it’s easier for some people to throw in the cards or just cope with the diagnosis,” Mr. Paskin said.” But Bill and Victoria have dedicated themselves to eradicating this disease.

“In light of all these obstacles, they still remain so positive, so motivated, and so inspiring,” he said.

Lauren Lundy O’Connor traveled from New York City to run in the marathon. She became passionate about finding a cure for SMA when her best friend’s son died from the disease a few years ago.

Ms. O’Connor, a second-grade teacher, said she connected with the Strongs on Facebook, became good friends with the family and has raised more than $20,000 for the foundation.

She said she is motivated by Gwendolyn’s strength — at 4 years old, Gwendolyn has already doubled the average life expectancy of a child diagnosed with SMA type I.

“Gwendolyn may be 4 years old, but she is my hero, because she is so strong,” Ms. O’Connor said. “She won’t stop fighting. She fights every day. That little girl has my heart.”

The Strong family has changed her perception of life, she said.

“Bad days aren’t really bad days. Every minute is really a gift and there are no guarantees. The way they give Gwendolyn the world teaches me not to take things for granted and to really appreciate the little things.”

While cheering on her husband and the rest of Team GSF at the marathon Saturday, Mrs. Strong was moved to tears by her team.

“The funny thing is they all want to thank us, but they are making a difference,” she said. “It’s easy to just say, ‘I’m really sorry,’ or ‘Their situation stinks,’ but they’re going to help change it and that’s incredible.”

Mrs. Strong stood with Mr. Paskin’s wife and Ms. O’Connor’s mother on the sidelines holding signs for their loved ones that read, “Team GSF” or “Never Give Up.”

The Strongs say they aim to make running the marathon an annual event for the foundation.

They hope to bring in more runners next year, which their supporters say they will have no problem doing. It seems they all have inspired each other.

“It would take an unbelievable amount of endurance to give Gwendolyn the quality of life they have and I think the group of us understand there’s a similarity there,” Mr. Paskin said.

Ms. O’Connor agrees. She said the Strong family’s dedication keeps her running. “I plan to run as long as I’m alive or until there is a cure for the disease, whichever comes first,” she said.

email: ngrey@newspress.com

Click HERE or on the image below to read more…


Gwendolyn Strong Foundation Freshens Brand, Launches New Website and Online Store

November 8, 2011

Gwendolyn Strong Foundation Freshens Brand, Launches New Website and Online Store

Press Release | November 7, 2011

The Gwendolyn Strong Foundation (theGSF), a Santa Barbara-based nonprofit organization dedicated to increasing global awareness of Spinal Muscular Atrophy (SMA), the #1 genetic killer of young children, and accelerating research focused on ending this cruel disease, has refreshed its brand and launched a new website, blog, and online store offering trendy merchandise featuring their new “NEVER GIVE UP.” slogan.

“We received our nonprofit exemption in August 2009 and since then we have accomplished so much,” said Victoria Strong, theGSF co-founder. “With the support of countless around the globe, we’ve raised nearly $1 Million, increased awareness of SMA, and have had a material impact on this brutal disease. But there is still much work to be done. Children with SMA never give up and neither will we. Our new brand and online presence clearly reflects where we’ve been and paves the way for our strategic direction as we look to the future.”

To explore the new theGSF website, please visit http://theGSF.org.

To browse the new theGSF shop, please visit http://theGSF.org/shop.

To make a tax-deductible donation to theGSF, please visit http://theGSF.org/donate.

About SMA: SMA is a terminal, degenerative genetic disease that impacts the voluntary muscles in infants and children, including the ability to walk, sit, stand, eat, breathe, and even swallow, while cognitive ability is never affected. Ninety percent of children born with SMA die before the age of two. One in every 40 people or nearly 175 Million globally unknowingly carry the gene responsible for SMA. There is currently no treatment or cure and although SMA research is underfunded, it is extremely advanced. theGSF is focused on helping ensure resources are not the obstacle in attaining that cure.

About Gwendolyn Strong Foundation (theGSF) – theGSF is based in Santa Barbara, California and seeks to increase awareness and research funding for Spinal Muscular Atrophy (SMA), the leading genetic killer of young children. To learn more about SMA and theGSF, please visit http://theGSF.org.

Click HERE or on the image below to read more…


Thirty Santa Barbara Marathon Runners Raise Over $43,000 for the Gwendolyn Strong Foundation

November 5, 2011

Thirty Santa Barbara Marathon Runners Raise Over $43,000 for the Gwendolyn Strong Foundation

Press Release | November 4, 2011

Online PR News – 03-November-2011 –Thirty Santa Barbara Marathon runners from around the country collectively raised over $43,000 for the Gwendolyn Strong Foundation (GSF), a Santa Barbara-based nonprofit organization dedicated to increasing awareness of Spinal Muscular Atrophy (SMA), the #1 genetic killer of young children, and accelerating research focused on a cure.

The thirty “Team GSF” runners will congregate in Santa Barbara to participate in the Santa Barbara International Marathon on November 12, 2011. Team members hail from California to New York and include GSF co-founder and father to Gwendolyn, Bill Strong, other SMA parents, families, and friends, and individuals moved by GSF’s efforts and the SMA cause. Beyond funding for SMA, Team GSF has also raised much needed awareness of SMA, its shocking statistics, its brutal progression, and its dire prognosis.

“To say we’re humbled by what the thirty inspiring Team GSF Santa Barbara Marathon runners have accomplished would be an enormous understatement,” said Bill Strong, GSF co-founder. “There is something unbelievably powerful about a group of individuals coming together to challenge and push their physical strength to the limits to help conquer a disease that robs children of theirs. We’ve all committed to running because we can and we’re running so one day those with SMA can too.”

Click HERE or on the image below to read more…


USC Scientist Targets the No. 1 Genetic Cause of Infant Mortality

October 18, 2011

USC Scientist Targets the No. 1 Genetic Cause of Infant Mortality

HealthCanal.com | October 13, 2011

The disease is heartbreaking. It turns babies into ragdolls and extinguishes lives just as they are getting started. But one USC scientist is working to unravel the mystery behind the leading genetic cause of infant mortality, uncovering how Spinal Muscular Atrophy disconnects muscles from the mind.

Spinal Muscular Atrophy, or SMA, is a neurodegenerative disease caused by a recessive gene mutation that results in a deficiency of the Survival of Motor Neuron, or SMN, protein. In a phenomenon called “denervation,” neurons lose their physical connection to muscles, resulting in a loss of motor control and muscle weakness.

A team of researchers lead by Chien-Ping Ko of the USC Dornsife College of Letters, Arts and Sciences has generated the first extensive study of severe denervation occurring in specific muscles affected by SMA. The data allows them to measure the effectiveness of drug treatments, and will act as a springboard for future research that explores the cause of SMA.

Click HERE or on the image below to read more…